Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1793 |
Name | pancreatic cancer |
Definition | An endocrine gland cancer located_in the pancreas. |
Source | DiseaseOntology.org |
Alt Ids | DOID:14356 DOID:1797 DOID:9859 DOID:3588 |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 loss | Adavosertib + Gemcitabine | pancreatic cancer | sensitive | detail... |
CDKN2A loss | Gemcitabine + Palbociclib | pancreatic cancer | decreased response | detail... |
CDKN2A loss | GSK461364 + Palbociclib | pancreatic cancer | decreased response | detail... |
CDKN2A loss | HMN-214 + Palbociclib | pancreatic cancer | decreased response | detail... |
KDR wild-type | Elpamotide + Gemcitabine | pancreatic cancer | sensitive | detail... |
BRAF V487_P492delinsA | LY3009120 | pancreatic cancer | sensitive | detail... |
BRAF V487_P492delinsA | Trametinib | pancreatic cancer | sensitive | detail... |
BRAF V487_P492delinsA | Vemurafenib | pancreatic cancer | resistant | detail... |
BRAF V487_P492delinsA | Dabrafenib | pancreatic cancer | resistant | detail... |
KDR positive | TAS-115 | pancreatic cancer | sensitive | detail... |
ROS1 positive | Entrectinib | pancreatic cancer | predicted - sensitive | detail... |
BRAF mutant | KO-947 | pancreatic cancer | predicted - sensitive | detail... |
NRAS mutant | KO-947 | pancreatic cancer | predicted - sensitive | detail... |
CDKN2A mutant | N/A | pancreatic cancer | not applicable | detail... |
MLH1 mutant | N/A | pancreatic cancer | not applicable | detail... |
MSH6 mutant | N/A | pancreatic cancer | not applicable | detail... |
NTRK1 fusion | Larotrectinib | pancreatic cancer | sensitive | detail... |
AXL positive | ADCT-601 | pancreatic cancer | sensitive | detail... |
BRAF N486_P490del | Dabrafenib | pancreatic cancer | predicted - sensitive | detail... |
CDKN2A loss | Palbociclib | pancreatic cancer | no benefit | detail... |
CDKN2A mutant | Palbociclib | pancreatic cancer | no benefit | detail... |
RET fusion | Pralsetinib | pancreatic cancer | predicted - sensitive | detail... |
ERBB3 positive | ISU104 | pancreatic cancer | sensitive | detail... |
BRAF class 2 | Exarafenib | pancreatic cancer | predicted - sensitive | detail... |
EML4 - ALK | Alectinib | pancreatic cancer | predicted - sensitive | detail... |
EML4 - ALK | Crizotinib | pancreatic cancer | predicted - sensitive | detail... |
ATM R1882* ATM R3008H | Berzosertib + Irinotecan | pancreatic cancer | predicted - sensitive | detail... |
RET fusion | Selpercatinib | pancreatic cancer | predicted - sensitive | detail... |
MSH6 negative | Pembrolizumab | pancreatic cancer | sensitive | detail... |
MLH1 negative | Pembrolizumab | pancreatic cancer | sensitive | detail... |
BRAF V487_P492delinsA | IHMT-RAF-128 | pancreatic cancer | sensitive | detail... |
BRAF V487_P492delinsA ERBB3 pos | AMT-562 | pancreatic cancer | sensitive | detail... |
NTRK2 fusion | Larotrectinib | pancreatic cancer | sensitive | detail... |
NTRK2 fusion | Entrectinib | pancreatic cancer | sensitive | detail... |
NTRK1 fusion | Entrectinib | pancreatic cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00871169 | Phase II | Cetuximab + Irinotecan + Oxaliplatin | Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT00892736 | Phase I | Veliparib | Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy | Completed | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT01384253 | Phase I | 212Pb-TCMC-Trastuzumab + Trastuzumab | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | Completed | USA | 0 |
NCT01497392 | Phase I | Gemcitabine Dovitinib Capecitabine | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | Completed | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01676259 | Phase II | Gemcitabine + Nab-paclitaxel + siG12D-LODER Gemcitabine + Nab-paclitaxel | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT) | Unknown status | USA | 1 |
NCT01822756 | Phase I | Ruxolitinib | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01888965 | Phase II | Dovitinib | Maintenance Dovitinib for Colorectal and Pancreas Cancer | Terminated | USA | 0 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | GBR | ESP | DEU | CAN | 2 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | AUS | 1 |
NCT01989546 | Phase Ib/II | Talazoparib | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | Completed | USA | 0 |
NCT02030067 | Phase Ib/II | RX-3117 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | Completed | USA | 0 |
NCT02048943 | Phase I | Dovitinib + Gemcitabine + Nab-paclitaxel Nab-paclitaxel Dovitinib | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02154737 | Phase I | Erlotinib + Gemcitabine | Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02237157 | Phase I | Gemcitabine | A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer | Completed | USA | 0 |
NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
NCT02305186 | Phase Ib/II | Pembrolizumab Capecitabine | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | Unknown status | USA | 0 |
NCT02341625 | Phase Ib/II | BMS-986148 BMS-986148 + Nivolumab | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | Terminated | USA | ITA | GBR | CAN | BEL | AUS | 1 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02451553 | Phase I | Afatinib Capecitabine | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | Completed | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02546531 | Phase I | Defactinib + Gemcitabine + Pembrolizumab | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT02559674 | Phase Ib/II | ALT-803 + Gemcitabine + Nab-paclitaxel | ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel | Completed | USA | 0 |
NCT02576665 | Phase I | Toca 511 + Toca FC | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02581215 | Phase II | Ramucirumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02661542 | Phase Ib/II | FF-10502 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT02671955 | Phase I | Onvatilimab | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02713529 | Phase Ib/II | AMG 820 + Pembrolizumab | Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | Completed | USA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Completed | USA | AUS | 5 |
NCT02744287 | Phase Ib/II | BPX-601 + Rimiducid | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | Suspended | USA | 0 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
NCT02829099 | Phase I | JNJ-64457107 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Completed | ESP | 1 |
NCT02829723 | Phase Ib/II | BLZ945 BLZ945 + Spartalizumab | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Terminated | USA | ITA | ESP | 5 |
NCT02897375 | Phase I | Cisplatin + Palbociclib Carboplatin + Palbociclib | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02912949 | Phase Ib/II | Zenocutuzumab | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 8 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CAN | AUT | 4 |
NCT02950064 | Phase I | BTP-114 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | Unknown status | USA | 0 |
NCT02953782 | Phase Ib/II | Cetuximab + Hu5F9-G4 | Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT02983578 | Phase II | Danvatirsen + Durvalumab | AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03023722 | Phase II | Anetumab ravtansine | Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer | Completed | USA | 0 |
NCT03033225 | Phase II | Verteporfin | EUS-guided PDT in Pancreatic Tumors | Recruiting | USA | 0 |
NCT03040986 | Phase II | Selumetinib | Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations | Completed | USA | 0 |
NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
NCT03080974 | Phase II | Nivolumab | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03087591 | Phase I | APN401 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03098160 | Phase I | Evofosfamide + Ipilimumab | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | Unknown status | USA | 0 |
NCT03136406 | Phase Ib/II | GI-4000 Leucovorin Avelumab Nab-paclitaxel Bevacizumab Cyclophosphamide Capecitabine Oxaliplatin Fluorouracil ETBX-011 ALT-803 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Unknown status | USA | 0 |
NCT03161379 | Phase II | Cyclophosphamide + GVAX pancreatic cancer vaccine + Nivolumab | Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03184870 | Phase Ib/II | BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT03189914 | Phase Ib/II | RX-3117 | RX-3117 in Combination With Abraxane in Subjects With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT03207867 | Phase II | Spartalizumab + Taminadenant | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS | 7 |
NCT03257761 | Phase I | Durvalumab + Guadecitabine | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | Active, not recruiting | USA | 0 |
NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Recruiting | USA | GBR | 0 |
NCT03329248 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin ALT-803 + Avelumab + Bevacizumab + ETBX-011 + GI-4000 Capecitabine + Cyclophosphamide + Nab-paclitaxel | QUILT-3.060: Combination Immunotherapy With High-affinity Natural Killer (haNK) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy. | Unknown status | USA | 0 |
NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |
NCT03454035 | Phase I | Palbociclib + Ulixertinib | Phase I Trial of Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | Recruiting | USA | 0 |
NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
NCT03485209 | Phase II | Tisotumab vedotin-tftv | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03599362 | Phase II | Cabiralizumab + Nivolumab | Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer | Terminated | USA | 0 |
NCT03601923 | Phase II | Niraparib | Niraparib in Patients With Pancreatic Cancer | Recruiting | USA | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03784677 | Phase I | SOR-C13 | SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT03785210 | Phase II | Nivolumab + Tadalafil + Vancomycin | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | Completed | USA | 0 |
NCT03819387 | Phase I | NBF-006 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Active, not recruiting | USA | ITA | GBR | 3 |
NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of Defactinib and VS-6766. (FRAME) | Active, not recruiting | GBR | 0 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Active, not recruiting | USA | 0 |
NCT03900442 | Phase I | GGTI-2418 | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies | Unknown status | AUS | 0 |
NCT03915678 | Phase II | Atezolizumab + BDB001 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | Recruiting | FRA | 0 |
NCT03919292 | Phase Ib/II | Divalproex sodium + Neratinib | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | Recruiting | USA | 0 |
NCT03943004 | Phase I | DFP-14927 | Trial of DFP-14927 in Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Active, not recruiting | USA | 0 |
NCT04105335 | Phase I | CEBPA-51 + Pembrolizumab | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT) | Active, not recruiting | GBR | 0 |
NCT04117087 | Phase I | Ipilimumab + Nivolumab + Poly ICLC | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer | Recruiting | USA | 0 |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | GBR | AUS | 0 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Recruiting | USA | AUS | 3 |
NCT04156087 | Phase II | Durvalumab + Gemcitabine + Tremelimumab | Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC) | Active, not recruiting | BEL | 0 |
NCT04182516 | Phase I | NMS-03305293 | Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors | Recruiting | USA | ITA | 1 |
NCT04203641 | Phase Ib/II | Doxorubicin + L-DOS47 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Recruiting | USA | 0 |
NCT04222413 | Phase I | Metarrestin | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Active, not recruiting | USA | GBR | ESP | DEU | 1 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04294576 | Phase I | BJ-001 + Pembrolizumab BJ-001 | Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) | Recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) | Recruiting | USA | 0 |
NCT04367675 | Phase I | INO-5401 INO-5401 + INO-9012 | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Recruiting | USA | 0 |
NCT04390243 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | Active, not recruiting | USA | 0 |
NCT04390399 | Phase II | Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + PD-L1.t-haNK cells Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04421820 | Phase I | BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Active, not recruiting | USA | CAN | 1 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Active, not recruiting | USA | ITA | GBR | ESP | CAN | BEL | AUS | 8 |
NCT04550494 | Phase II | Talazoparib | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Recruiting | USA | 0 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Nivolumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Recruiting | USA | ESP | 0 |
NCT04616534 | Phase I | BAY1895344 + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |
NCT04673448 | Phase I | Dostarlimab-gxly + Niraparib | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT04683939 | Phase Ib/II | BNT141 BNT141 + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Active, not recruiting | USA | ESP | CAN | 0 |
NCT04705818 | Phase II | Durvalumab + Tazemetostat | Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) | Recruiting | FRA | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Recruiting | USA | ESP | 1 |
NCT04799431 | Phase I | Neoantigen peptide vaccine + Poly ICLC + Retifanlimab | Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | Withdrawn | 0 | |
NCT04858334 | Phase II | Olaparib | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Recruiting | USA | 0 |
NCT04870034 | Phase I | Binimetinib + Palbociclib | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | Recruiting | USA | 0 |
NCT04890613 | Phase I | CX-5461 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Recruiting | USA | CAN | 0 |
NCT04898543 | Phase I | ALT-803 + m-ceNK cells | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT04953962 | Phase II | CBP501 + Cisplatin + Nivolumab Cisplatin + Nivolumab CBP501 + Cisplatin | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ESP | 1 |
NCT05053971 | Phase Ib/II | Entinostat + ZEN-3694 | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | Recruiting | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05068752 | Phase II | Sorafenib + Vemurafenib | Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer | Recruiting | USA | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Recruiting | FRA | 1 |
NCT05239182 | Phase II | 9-ING-41 + Gemcitabine + Nab-paclitaxel + Retifanlimab | 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) | Active, not recruiting | USA | 0 |
NCT05251038 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Sotorasib Fluorouracil + Leucovorin + MM-398 + Sotorasib | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | Withdrawn | USA | 0 |
NCT05252390 | Phase Ib/II | NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05259696 | Phase Ib/II | E-602 E-602 + Pembrolizumab | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) | Recruiting | USA | 0 |
NCT05293496 | Phase I | MGC018 + MGD019 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05304936 | Phase Ib/II | HCW9218 | HCW9218 for Advanced Pancreatic Cancer | Recruiting | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05360680 | Phase I | CUE-102 | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Recruiting | USA | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05411094 | Phase I | Durvalumab + Olaparib | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | Suspended | USA | CAN | 0 |
NCT05417594 | Phase Ib/II | AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | GBR | ESP | DEU | AUS | 2 |
NCT05571839 | Phase I | SGN-BB228 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Recruiting | USA | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05634525 | Phase I | Adagrasib | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients | Recruiting | USA | 0 |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Recruiting | USA | 1 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05694715 | Phase I | Irinotecan + Niraparib | Combination Therapy in Cancers With Mutations in DNA Repair Genes | Recruiting | USA | 0 |
NCT05733000 | Phase II | CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | Recruiting | USA | 0 |
NCT05736731 | Phase Ib/II | A2B530 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) | Recruiting | USA | 0 |
NCT05800964 | Phase I | AMG 305 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. | Recruiting | USA | AUS | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05944276 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT05980416 | Phase I | EO-3021 | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Recruiting | 0 | |
NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Not yet recruiting | 0 | |
NCT06036121 | Phase I | ADRX-0706 | A Study of ADRX-0706 in Select Advanced Solid Tumors | Recruiting | 0 |